News
June 18, 2019

Regenstrief scientist explains how class of drugs may be related to dementia

Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show.

Dr. Campbell was a guest on Caregiver Crossing, which airs every Saturday on 93.1 WIBC. Dr. Campbell addressed the topic of anticholinergics and their potential link to Alzheimer’s and dementia. Anticholinergics are a common class of drug that includes some allergy medications, sleeping pills and many more common medicines.

Dr. Campbell recently received a $3.3 million grant from the National Institute on Aging to conduct the first clinical trial designed to determine if stopping these medications results in sustained improvements in cognition.

Listen to his discussion with the Caregiver Crossing hosts and his advice for people who are taking these medications.

Segment 1

Segment 2

Click here for more information on Caregiver Crossing.

  • Noll Campbell, PharmD, MS

Related News

Matt Bair, MD

Regenstrief researcher appointed deputy chief of research and development service at Richard L. Roudebush VA Medical Center

Matthew Bair, M.D., M.S., a research scientist at the Regenstrief Institute and professor of medicine at the Indiana University

Arthur Owora, PhD

Machine learning tool improves pediatricians’ ability to identify children at risk for persistent asthma 

Pilot randomized trial finds EHR-integrated decision support improved clinicians’ prediction of school-age asthma  A machine learning tool that analyzes

Health First Indiana generated estimated $742.6 million in savings through key public health services

An analysis from the Regenstrief Institute found that Health First Indiana (HFI), the state’s landmark public health funding initiative,

Office of Strategic Innovation helps connect startups with research expertise

Moving healthcare innovations from promising ideas to real-world impact requires collaboration between researchers, entrepreneurs, healthcare organizations and industry partners.